Pulmatrix Inc. (PULM)
PULM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.38
-3.50% on the day
Market cap
$5.0M
Nano cap
Revenue · 2024
$7.8M
+7.0% on 2023
Net income · 2024
-$9.6M
-122.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2024.
Profile
| Field | Value |
|---|---|
| Ticker | PULM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001574235 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $7.8M |
| Net income | -$9.6M |
| Operating income | -$9.8M |
| Net margin | -122.5% |
| Operating margin | -125.1% |
| Revenue growth | +7.0% |
| Cash | $9.5M |
| Total assets | $9.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-07 |
| Latest annual report | 10-K/A | 2026-06-16 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-08-13 |
| Latest proxy | DEFA14A | 2026-10-07 |
Source: SEC EDGAR submissions feed, 647 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KALA | KALA BIO Inc. | $0.2600 | -7.14% | $5.0M |
| ADXN | Addex Therapeutics Ltd | $3.01 | -0.99% | $5.1M |
| PCSA | Processa Pharmaceuticals Inc. | $1.77 | -6.84% | $5.0M |
| GELS | Gelteq Limited | $0.4801 | -2.06% | $5.1M |
| XBIO | Xenetic Biosciences Inc. | $2.10 | -0.94% | $4.9M |
| XTLB | XTL Biopharmaceuticals Ltd. | $1.98 | +3.12% | $4.9M |
| SCNX | Scienture Holdings Inc. | $3.24 | -17.14% | $5.3M |
| LNAI | Lunai Bioworks Inc. | $1.03 | -7.21% | $4.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier